ATOS — Q2 2026 Financial Report Analysis

Q2 2026: a steady $8.5 million loss, but the cash clock is now the story

Atossa Therapeutics is a clinical-stage biotech — it has no approved product and no sales, so it pays for its research out of cash raised from investors. Its only drug candidate is (Z)-endoxifen, an oral pill derived from the active form of the breast-cancer drug tamoxifen, which is being tested in four Phase 2 trials (mid-stage human studies that look for signs the drug works, after early safety testing and before the large trials needed for approval).

In the quarter ended June 30, 2026, Atossa lost $8.5 million, almost exactly the $8.4 million it lost a year earlier. Lower research spending was offset by higher legal costs and much lower interest income. The bigger change is on the balance sheet: cash fell to $26.1 million, from $41.3 million at the end of 2025 and $57.9 million a year ago, and the 10-Q says there is "substantial doubt" about the company's ability to keep operating — the formal going-concern warning — and that current resources "will likely be insufficient" to fund planned operations for the next twelve months.

At a glance

• $26.1 million in cash, burning about $9.6 million a quarter — at the first-half pace that funds roughly two and a half to three more quarters, which is why the filing carries a going-concern warning and why more share sales are likely.
• $8.5 million net loss (–$0.95 per share) — flat in dollars versus a year ago; the per-share loss looks slightly smaller only because there are more shares outstanding after a June stock sale.
• $4.0 million raised in June at $3.30 per share plus warrants — a small raise relative to the burn, and it diluted holders by about 16% (1.36 million new shares on 8.6 million).

The numbers

Percentage changes on revenue, margin and earnings are marked "n/m" (not meaningful): Atossa has no revenue, so a margin can't be computed, and a percentage change between two losses says little. Per-share figures for both years reflect the 1-for-15 reverse stock split on February 2, 2026 (every 15 old shares became one new share).

Where the money went

Research and development fell 11% to $4.9 million in the quarter. The filing attributes the drop to $1.0 million less spending on preclinical (laboratory and animal) studies that finished in 2025, partly offset by $0.2 million more from higher patient enrollment in clinical trials and $0.3 million more in drug-development costs. Over the six months, R&D was flat at $9.7 million: clinical-trial enrollment costs rose $1.5 million and drug development $0.7 million, while finished preclinical work saved $1.8 million. In other words, money is shifting from lab work toward human trials — the expensive part.

General and administrative costs rose 7% to $3.8 million in the quarter and 31% to $8.9 million for the half. The cause is legal bills: legal fees were up $0.7 million in the quarter and $2.5 million in the half, mostly from patent disputes with Intas Pharmaceuticals over Atossa's endoxifen patents, plus intellectual-property and SEC-compliance work. Staff costs in G&A fell 15–20% on lower headcount.

Interest income dropped to $0.2 million from $0.6 million because there is far less cash sitting in the money-market account earning interest. That alone accounts for most of why the net loss didn't shrink alongside operating expenses.

What the headline numbers hide

• Cash going out faster than the loss suggests. For the first half, the company used $19.2 million of cash in operations against an $18.1 million net loss. The gap comes mainly from paying down $2.3 million of bills owed to suppliers (accounts payable fell from $4.3 million to $2.0 million), partly offset by $1.5 million of stock-based pay that is an expense but not a cash outflow. Cash burn was up $6.0 million year on year; the filing attributes $4.2 million of that to legal, accounting and other professional fees, $1.5 million to trials and drug development, and $0.8 million to lower interest income, with fewer employees saving $0.5 million despite severance payments.
• A one-off that should fade. The patent fight with Intas and Jina Pharmaceuticals was settled on April 13, 2026; two of Atossa's endoxifen patents remain in force. The extra $2.5 million of first-half legal fees should not recur at that scale, which would bring quarterly burn down somewhat — but the filing gives no figure for how much.
• The runway warning has hardened. In its annual report filed in March, management said existing resources "should be sufficient" for at least the next 12 months. By the Q1 10-Q in May that had flipped to "will likely be insufficient," and the Q2 10-Q repeats it. At the first half's average burn of about $9.6 million a quarter, $26.1 million lasts until roughly early 2027 without new money. There are also $4.3 million of non-cancellable trial contracts still to be paid.
• The June raise was small and dilutive. Atossa sold 1,363,637 shares at $3.30, each with two warrants (rights to buy more shares later) at $4.40, netting $4.0 million after $0.5 million in fees. The warrants could bring in up to $12 million more, but only if holders choose to pay $4.40 per share, 33% above the price of the offering — so that cash depends on the stock rising. A separate $50 million "at-the-market" program (selling shares gradually into the market) raised just $21,000 in the quarter.
• The per-share loss improvement is share count, not operations. Loss per share went from –$0.98 to –$0.95 only because the average share count rose 3% (8.91 million vs. 8.62 million) while the dollar loss was flat.
• A key data timeline slipped. The Q1 10-Q said top-line data from the Karisma trial (below) would come in the first half of 2026. The Q2 10-Q moved this to "before the end of the third quarter of 2026." As of October 5, Atossa had not filed an 8-K reporting those results.

Takeaway: Atossa's quarterly spending is stable at under $9 million, but with $26.1 million in cash and its own filing saying that won't last twelve months, the next year depends on raising money — and how much existing holders get diluted depends on whether upcoming trial readouts give the stock a reason to rise first.

The pipeline: what's being tested

All four Phase 2 trials test the same molecule in different settings:

• Karisma — low-dose (Z)-endoxifen to reduce breast density on mammograms (dense breast tissue raises breast-cancer risk and makes tumors harder to spot). The 240-woman Swedish trial already reported that 1 mg and 2 mg daily doses cut density by 17.3% and 23.5% over six months, versus 0.27% on placebo. The pending readout is whether that reduction lasted over 24 months.
• I-SPY 2 — (Z)-endoxifen given before surgery (neoadjuvant) to early-stage ER+/HER2– breast cancer patients, the most common type, whose tumors grow in response to estrogen. At 10 mg, the filing cites a median 72% reduction in MRI-measured tumor volume and falling Ki-67 (a marker of how fast cancer cells divide). A 40 mg arm combined with Eli Lilly's abemaciclib or AbbVie's elagolix has finished enrolling, with data expected "throughout the second half of 2026."
• EVANGELINE — 40 mg plus ovarian suppression in premenopausal women before surgery; enrollment completed as of June 30. The early run-in phase showed about 86% of patients reaching Ki-67 of 10% or less at week 4, against a 65% success threshold.
• RECAST DCIS — tests whether hormone therapy plus MRI can let women with low-risk early lesions (DCIS) safely skip surgery; enrolling.

Beyond oncology, the FDA has granted (Z)-endoxifen Rare Pediatric Disease designations for Duchenne muscular dystrophy (DMD) and McCune-Albright syndrome, and Orphan Drug designation for DMD. If a drug with a rare pediatric designation is eventually approved, the FDA can award a "priority review voucher," which companies sell to other drugmakers. On September 29, after the quarter closed, Atossa announced a plan to give shareholders a contingent value right (CVR) entitling them, together, to 25% of net proceeds from its first voucher, capped at $50 million. No DMD or MAS trial is described as under way in the 10-Q, so a voucher is years away at best, and the company says no payment is assured.

Outlook

Management gives no financial guidance. The near-term milestones it has stated are the Karisma 24-month durability data (promised for Q3 2026, not yet announced as of October 5) and I-SPY 40 mg combination data during the second half of 2026; it also plans to seek Orphan Drug designation for MAS in the second half.

Our read: the operating picture is stable — quarterly R&D near $5 million, and G&A should ease now that the patent litigation is settled. The binding constraint is cash. With roughly two to three quarters of funding at the current burn, Atossa will need to raise money before most of its Phase 2 programs can turn into a larger, approval-oriented trial, which typically costs far more than its entire current cash balance. The things to watch next quarter are (1) whether the Karisma and I-SPY data arrive and are strong enough to support a raise on better terms than June's $3.30, (2) the size of quarterly cash burn once legal fees fall away, and (3) how many new shares get issued through the at-the-market program or another offering.